December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

73.28 -0.99 (-1.34%)
Streaming Delayed Price Updated: 2:49 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
BridgeBio Shares Fall As Initial-Stage Rare Metabolic Disorder Study Kicks-off ↗
BridgeBio Pharma (NASDAQ: BBIO) has dosed first patient in its Phase 1 clinical trial of BBP-671, an investigational oral therapy being developed for the potential treatment of conditions caused by... 
Via Benzinga
News headline image
BridgeBio Starts Dosing In Early-Stage Genetic Metabolism Disorder Trial ↗
 
Via Benzinga
News headline image
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
BridgeBio Pharma Touts Encouraging Data From Dwarfism Candidate ↗
 
Via Benzinga
News headline image
BridgeBio Pharma Posts Promising Data From Gene Therapy Trial In Ultra-Rare Disease ↗
 
Via Benzinga
News headline image
BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
  
Via Benzinga
News headline image
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday ↗
Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1. 
Via Benzinga
News headline image
Where BridgeBio Pharma Stands With Analysts ↗
BridgeBio Pharma (NASDAQ:BBIO) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
BridgeBio Shares Plunge After it Details Out-Licensing Plans For 'Restructuring Initiative' ↗
 
Via Benzinga
News headline image
BridgeBio Pharma Highlights Mid-Stage Study Data Of Acoramidis In Cardiomyopathy Trial ↗
BridgeBio Pharma Inc (NASDAQ: BBIO)  
Via Benzinga
News headline image
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary ↗
 
Via Benzinga
News headline image
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reveals Early Positive Data For Canavan Disease ↗
BridgeBio Pharma (NASDAQ: BBIO) announced early positive data from the the first two participants dosed in CANaspire clinical study for the treatment of Canavan disease. 
Via Benzinga
News headline image
BridgeBio Pharma's Return On Capital Employed Insights ↗
Benzinga Pro data, BridgeBio Pharma (NASDAQ:BBIO) reported Q1 sales of $1.69 million. Earnings fell to a loss of $201.33 million, resulting in a 32.21% decrease from last quarter. 
Via Benzinga
News headline image
89 Biggest Movers From Friday ↗
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
News headline image
6 Analysts Have This to Say About BridgeBio Pharma ↗
Over the past 3 months, 6 analysts have published their opinion on BridgeBio Pharma (NASDAQ:BBIO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
News headline image
BridgeBio Partnered Protein Replacement Therapy Shows Promising Action In Painful Skin Blistering Disorder ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
What 6 Analyst Ratings Have To Say About BridgeBio Pharma ↗
BridgeBio Pharma (NASDAQ:BBIO) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
News headline image
Where BridgeBio Pharma Stands With Analysts ↗
Analysts have provided the following ratings for BridgeBio Pharma (NASDAQ:BBIO) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
News headline image
BridgeBio Pharma Posts Updated Data From Muscular Dystrophy Trial, Plots Path To Market ↗
BridgeBio Pharma Inc (NASDAQ: BBIO) has announced data from the Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i), a group... 
Via Benzinga
News headline image
Sentynl Buys BridgeBio Pharma's Fosdenopterin Rights In Genetic Disorder ↗
BridgeBio Pharma Inc (NASDAQ: BBIO) has agreed to sell Nulibry (fosdenopterin) for injection to Sentynl Therapeutics Inc, owned by Zydus Lifesciences Ltd.... 
Via Benzinga
News headline image
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
News headline image
Helsinn, BridgeBio Pharma Amend Infigratinib Pact For Oncology Indications ↗
Helsinn Group and BridgeBio Pharma Inc (NASDAQ: BBIO) have updated their existing strategic collaboration to develop, manufacture, and commercialize... 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.